ArticlePloS one2026
Analysis of morphological, morphokinetics, cell-free DNA, microRNAs parameters to predict aneuploidy status of embryos.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Vitro Fertilization (IVF) is one of the most effective infertility treatments. Preimplantation genetic testing for aneuploidy (PGT-A) is invasive, high-cost, and has the potential risk of embryo damage. Our study explores noninvasive approaches to assess embryo quality through morphology and morphokinetics and analyze miRNA, cell-free DNA (cfDNA) for embryo chromosomal status.
methodsThis cross-sectional study followed the STROBE guideline. We analysed the relationship between embryo morphology, morphokinetics, cfDNA, and microRNAs with the aneuploidy status of day-5 embryos at the blastocyst stage. Non-probability consecutive sampling yielded 124 embryos between 28th December 2021 and 31st December 2022 in our center. Model performance was evaluated using the area under the curve (AUC) from receiver operating characteristic (ROC) analysis.
resultsOf 124 embryos, 50.8% had aneuploid chromosomes. Analysis of ccfDNA demonstrated a significantly higher rate of aneuploidy from aneuploid embryos compared to the euploid group (p < 0.001). Morphokinetic parameters assessment showed longer pronuclear fading time (21.9 vs. 19.9 hours; p = 0.041) and shorter third cell cycle synchrony (13.4 vs. 17.5 hours; p = 0.036). The expression of miRNA-191 and miRNA-372 was higher in aneuploid compared to euploid embryos (8.1 fold, p < 0.001, and 6.5 fold, p = 0.008, respectively). ROC analysis revealed predictive values for miRNA-191 (AUC 0.745, sensitivity 73%, specificity 70.5%) and miRNA-372 (AUC 0.638, sensitivity 68.3%, specificity 55.7%). MiRNA-191, expansion category, and noninvasive PGT-A (niPGT-A) were identified as independent predictors of embryo ploidy status (p = 0.005).
conclusionEmbryo chromosomal status can be evaluated by integrating morphology, morphokinetics, miRNA-191, miRNA-372, and cell-free DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.